BioAtla announces preliminary data from Phase 1 study of BA3182

BioAtla (BCAB) announced preliminary clinical data from a Phase 1 study of BA3182 during a poster presentation titled “Preliminary Results from a First-in-Human Phase 1 Study of BA3182, a Dual-Conditionally Binding Biologic, CAB, EpCAM x CD3 Bispecific T-cell Engager in Patients with Treatment Refractory Metastatic Adenocarcinoma” at the European Society for Medical Oncology, ESMO, Congress 2025, held in Berlin, Germany. The poster was featured in the Investigational Immunotherapy session on Sunday, October 19. Key points: Adverse events generally transient and readily manageable; only 2 cases of cytokine release syndrome; Prolonged tumor control with increasing doses of BA3182; confirmed partial response at 0.6 mg in a patient with intrahepatic cholangiocarcinoma without progression for greater than6 months; Maximally tolerated dose not yet defined; dose escalation continues; currently testing 1.8 mg dose level